HK1203560A1 - 用於雙特異性抗體支架的經修飾的多肽 - Google Patents

用於雙特異性抗體支架的經修飾的多肽

Info

Publication number
HK1203560A1
HK1203560A1 HK15104067.3A HK15104067A HK1203560A1 HK 1203560 A1 HK1203560 A1 HK 1203560A1 HK 15104067 A HK15104067 A HK 15104067A HK 1203560 A1 HK1203560 A1 HK 1203560A1
Authority
HK
Hong Kong
Prior art keywords
bispecific antibody
modified polypeptides
antibody scaffolds
scaffolds
polypeptides
Prior art date
Application number
HK15104067.3A
Other languages
English (en)
Inventor
Partha S Chowdhury
Vaheh Oganesyan
Yariv Mazor
Nazzareno Dimasi
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of HK1203560A1 publication Critical patent/HK1203560A1/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • C07K16/248—IL-6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
HK15104067.3A 2011-12-20 2015-04-28 用於雙特異性抗體支架的經修飾的多肽 HK1203560A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161577956P 2011-12-20 2011-12-20
PCT/US2012/070310 WO2013096291A2 (en) 2011-12-20 2012-12-18 Modified polypeptides for bispecific antibody scaffolds

Publications (1)

Publication Number Publication Date
HK1203560A1 true HK1203560A1 (zh) 2015-10-30

Family

ID=48669692

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15104067.3A HK1203560A1 (zh) 2011-12-20 2015-04-28 用於雙特異性抗體支架的經修飾的多肽

Country Status (18)

Country Link
US (1) US9527927B2 (zh)
EP (1) EP2794905B1 (zh)
JP (1) JP6541974B2 (zh)
CN (1) CN104011221B (zh)
AU (1) AU2012355415B2 (zh)
CA (1) CA2859667C (zh)
CY (1) CY1123079T1 (zh)
DK (1) DK2794905T3 (zh)
ES (1) ES2816078T3 (zh)
HK (1) HK1203560A1 (zh)
HR (1) HRP20201004T1 (zh)
HU (1) HUE049457T2 (zh)
LT (1) LT2794905T (zh)
PL (1) PL2794905T3 (zh)
PT (1) PT2794905T (zh)
RS (1) RS60499B1 (zh)
SI (1) SI2794905T1 (zh)
WO (1) WO2013096291A2 (zh)

Families Citing this family (277)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090162359A1 (en) 2007-12-21 2009-06-25 Christian Klein Bivalent, bispecific antibodies
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
US9676845B2 (en) 2009-06-16 2017-06-13 Hoffmann-La Roche, Inc. Bispecific antigen binding proteins
RU2573915C2 (ru) 2009-09-16 2016-01-27 Дженентек, Инк. Содержащие суперспираль и/или привязку белковые комплексы и их применение
AR080793A1 (es) 2010-03-26 2012-05-09 Roche Glycart Ag Anticuerpos biespecificos
DK2635607T3 (da) 2010-11-05 2019-11-18 Zymeworks Inc Stabilt heterodimert antistofdesign med mutationer i fc-domænet
RU2620071C2 (ru) 2010-11-17 2017-05-22 Чугаи Сеияку Кабушики Каиша Мультиспецифическая связывающая антиген молекула, которая обладает альтернативной функцией к функции фактора свертывания крови viii
CA2824824A1 (en) 2011-02-28 2012-09-07 F. Hoffmann-La Roche Ag Monovalent antigen binding proteins
RU2607038C2 (ru) 2011-02-28 2017-01-10 Ф. Хоффманн-Ля Рош Аг Антигенсвязывающие белки
WO2013026839A1 (en) 2011-08-23 2013-02-28 Roche Glycart Ag Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
HRP20211773T1 (hr) 2011-11-04 2022-03-04 Zymeworks Inc. Stabilna heterodimerni dizajn antitijela s mutacijama u fc domeni
WO2013113008A1 (en) 2012-01-26 2013-08-01 Amgen Inc. Growth differentiation factor 15 (gdf-15) polypeptides
GB201203051D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
GB201203071D0 (en) * 2012-02-22 2012-04-04 Ucb Pharma Sa Biological products
CN105121630B (zh) 2012-10-03 2018-09-25 酵活有限公司 定量重链和轻链多肽对的方法
US10087250B2 (en) 2012-10-08 2018-10-02 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
WO2014069647A1 (ja) * 2012-11-05 2014-05-08 全薬工業株式会社 抗体又は抗体組成物の製造方法
KR102288394B1 (ko) * 2012-11-06 2021-08-09 메디뮨 엘엘씨 스타필로코커스 아우레우스 표면 결정인자에 대한 항체
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
BR112015012385A2 (pt) 2012-11-28 2019-08-27 Zymeworks Inc constructo de polipeptídeo de ligação de antígeno isolado, polinucleotídeo isolado ou conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do constructo, método para tratar um sujeito tendo uma doença ou distúrbio ou câncer ou doença vascular, método para inibir, reduzir ou bloquear um sinal dentro de uma célula, método para obter o constructo, método para preparar o constructo, meio de armazenamento legível por computador, método implementado por computador e método para produzir um constructo de polipeptídeo de ligação de antígeno bi-específico
MX2015010146A (es) * 2013-02-08 2016-05-31 Novartis Ag Sitios especificos para modificar anticuerpos para hacer inmunoconjugados.
KR102282761B1 (ko) 2013-02-26 2021-07-30 로슈 글리카트 아게 이중특이적 t 세포 활성화 항원 결합 분자
CA2896370A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
BR112015027385A2 (pt) 2013-04-29 2017-08-29 Hoffmann La Roche Anticorpos modificados de ligação ao fcrn humano e métodos de uso
CN105164158A (zh) 2013-04-29 2015-12-16 豪夫迈·罗氏有限公司 消除对FcRn-结合的抗-IGF-1R抗体及其在血管性眼病治疗中的用途
JP6618893B2 (ja) 2013-04-29 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｆｃ受容体結合が変更された非対称抗体および使用方法
CA2916521C (en) 2013-07-09 2023-03-07 Annexon, Inc. Anti-complement factor c1q antibodies and uses thereof
EP3763734A1 (en) * 2013-07-31 2021-01-13 Amgen Inc. Growth differentiation factor 15 (gdf-15) constructs
AU2014312215B2 (en) 2013-08-28 2020-02-27 Abbvie Stemcentrx Llc Site-specific antibody conjugation methods and compositions
KR102306492B1 (ko) 2013-09-05 2021-09-29 아이쥐엠 바이오사이언스 인코포레이티드 불변 쇄 변형된 이특이적, 5가 및 6가 ig-m 항체
EP3055329B1 (en) 2013-10-11 2018-06-13 F. Hoffmann-La Roche AG Multispecific domain exchanged common variable light chain antibodies
RU2016122041A (ru) 2013-11-06 2017-12-11 ЭББВИ СТЕМСЕНТРКС ЭлЭлСи Новые анти-клаудин антитела и способы их применения
JP2017500028A (ja) 2013-12-12 2017-01-05 アッヴィ・ステムセントルクス・エル・エル・シー 新規の抗ｄｐｅｐ３抗体および使用方法
ES2778498T3 (es) 2013-12-20 2020-08-10 Hoffmann La Roche Anticuerpos anti-tau(pS422) humanizados y procedimientos de uso
PL3089996T3 (pl) 2014-01-03 2021-12-13 F. Hoffmann-La Roche Ag Dwuswoiste przeciwciała przeciw haptenowi/przeciw receptorowi występującemu w barierze krew-mózg, ich kompleksy i ich zastosowanie jako przenośniki wahadłowe występujące w barierze krew-mózg
CA2932547C (en) 2014-01-06 2023-05-23 F. Hoffmann-La Roche Ag Monovalent blood brain barrier shuttle modules
RU2727639C2 (ru) 2014-01-15 2020-07-22 Ф.Хоффманн-Ля Рош Аг Варианты fc-области с модифицированной способностью связываться с fcrn и с сохраненной способностью связываться с белком а
EP3107576A4 (en) 2014-02-21 2017-09-06 Abbvie Stemcentrx LLC Anti-dll3 antibodies and drug conjugates for use in melanoma
JP6666262B2 (ja) 2014-04-02 2020-03-13 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体の軽鎖誤対合を検出するための方法
UA117289C2 (uk) 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
US10392438B2 (en) * 2014-05-16 2019-08-27 Pfizer Inc. Bispecific antibodies
WO2015181805A1 (en) 2014-05-28 2015-12-03 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
RU2705299C2 (ru) 2014-06-26 2019-11-06 Ф. Хоффманн-Ля Рош Аг Антитела против 5-бром-2'-дезоксиуридина и способы применения
AR100978A1 (es) 2014-06-26 2016-11-16 Hoffmann La Roche LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
KR102317315B1 (ko) 2014-08-04 2021-10-27 에프. 호프만-라 로슈 아게 이중특이적 t 세포 활성화 항원 결합 분자
EP2982692A1 (en) 2014-08-04 2016-02-10 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
TW201617368A (zh) 2014-09-05 2016-05-16 史坦森特瑞斯公司 新穎抗ｍｆｉ２抗體及使用方法
CN106922129B (zh) 2014-10-01 2024-02-20 免疫医疗有限责任公司 轭合多肽的方法
EP3204415B1 (en) 2014-10-09 2020-06-17 EngMab Sàrl Bispecific antibodies against cd3epsilon and ror1
EP4295911A3 (en) * 2014-11-05 2024-03-27 Annexon, Inc. Humanized anti-complement factor c1q antibodies and uses thereof
JP6576456B2 (ja) 2014-11-06 2019-09-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 修飾されたＦｃＲｎ結合特性およびプロテインＡ結合特性を有するＦｃ領域変種
BR112017006178A2 (pt) 2014-11-06 2018-05-02 F. Hoffmann-La Roche Ag região fc, anticorpos, formulação farmacêutica e usos dos anticorpos
SI3221357T1 (sl) 2014-11-20 2020-09-30 F. Hoffmann-La Roche Ag Pogoste lahke verige in načini uporabe
EP3023437A1 (en) 2014-11-20 2016-05-25 EngMab AG Bispecific antibodies against CD3epsilon and BCMA
EP3789402B1 (en) 2014-11-20 2022-07-13 F. Hoffmann-La Roche AG Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
JP6721590B2 (ja) 2014-12-03 2020-07-15 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 多重特異性抗体
WO2016109774A1 (en) * 2015-01-02 2016-07-07 Dyax Corp. Bispecific antibodies against plasma kallikrein and factor xii
CN104628851B (zh) * 2015-02-12 2019-07-30 长春百克生物科技股份公司 一种抗狂犬病毒的基因工程抗体、其制备方法和应用
JP6619460B2 (ja) 2015-06-24 2019-12-11 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ヒト化抗タウ（ｐＳ４２２）抗体及び使用法
EP3317299A1 (en) * 2015-06-30 2018-05-09 Boehringer Ingelheim International GmbH Multi-specific binding proteins
ME03772B (me) 2015-07-10 2021-04-20 Genmab As Konjugati antitijela specifičnog za axl i lijeka za liječenje kancera
KR20180096567A (ko) 2015-07-21 2018-08-29 다이액스 코포레이션 Xiia 인자의 단일클론 항체 저해제
WO2017034770A1 (en) 2015-08-26 2017-03-02 Bison Therapeutics Inc. Multispecific antibody platform and related methods
CN106519024A (zh) * 2015-09-15 2017-03-22 三生国健药业（上海）股份有限公司 一种用于去除单克隆抗体中异构体的复性液及复性方法
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
WO2017055393A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xtim-3 bispecific t cell activating antigen binding molecules
AR106365A1 (es) 2015-10-02 2018-01-10 Hoffmann La Roche Moléculas biespecíficas de unión a antígeno activadoras de células t
WO2017055399A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Cellular based fret assay for the determination of simultaneous binding
EP3150637A1 (en) 2015-10-02 2017-04-05 F. Hoffmann-La Roche AG Multispecific antibodies
US20180282410A1 (en) 2015-10-02 2018-10-04 Hoffmann-La Roche Inc. Anti-cd3xrob04 bispecific t cell activating antigen binding molecules
JP2018533930A (ja) 2015-10-02 2018-11-22 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性ｔ細胞活性化抗原結合分子
EP3913000A1 (en) 2015-10-02 2021-11-24 F. Hoffmann-La Roche AG Bispecific anti-cd19xcd3 t cell activating antigen binding molecules
WO2017055385A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xgd2 bispecific t cell activating antigen binding molecules
JP6622392B2 (ja) 2015-10-02 2019-12-18 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ｐｄ１とｔｉｍ３に特異的な二重特異性抗体
JP7044700B2 (ja) 2015-10-02 2022-03-30 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 二重特異性抗ｃｅａｘｃｄ３ ｔ細胞活性化抗原結合分子
WO2017055392A1 (en) 2015-10-02 2017-04-06 F. Hoffmann-La Roche Ag Anti-cd3xcd44v6 bispecific t cell activating antigen binding molecules
JP6932693B2 (ja) 2015-10-08 2021-09-08 ザイムワークス，インコーポレイテッド カッパ及びラムダ軽鎖を含む抗原結合ポリペプチド構築物及びその使用
MX2018005036A (es) 2015-10-29 2018-08-01 Hoffmann La Roche Anticuerpos y metodos de uso de anti-regiones de fragmentos cristalizables (fc) variantes.
BR112018010360A2 (pt) 2015-11-24 2018-12-04 Annexon Inc fragmentos fab de fator de complemento anti-c1q e utilizações dos mesmos
US20180271998A1 (en) 2015-12-04 2018-09-27 Merrimack Pharmaceuticals, Inc. Disulfide-stabilized fabs
EP3178848A1 (en) 2015-12-09 2017-06-14 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody for reducing formation of anti-drug antibodies
IL313608A (en) 2015-12-09 2024-08-01 Hoffmann La Roche Antibody against CD20 type II to reduce the formation of antibodies against drugs
MX2018008347A (es) 2016-01-08 2018-12-06 Hoffmann La Roche Metodos de tratamiento de canceres positivos para ace utilizando antagonistas de union a eje pd-1 y anticuerpos biespecificos anti-ace/anti-cd3.
WO2017132298A1 (en) 2016-01-27 2017-08-03 Medimmune, Llc Methods for preparing antibodies with a defined glycosylation pattern
WO2017165464A1 (en) 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
WO2017191101A1 (en) 2016-05-02 2017-11-09 F. Hoffmann-La Roche Ag The contorsbody - a single chain target binder
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
EP3463451A1 (en) * 2016-05-26 2019-04-10 Qilu Puget Sound Biotherapeutics Corporation Mixtures of antibodies
BR112019022558A2 (pt) 2016-06-02 2020-05-19 Hoffmann La Roche anticorpos, métodos para tratar ou retardar a progressão de uma doença proliferativa e para tratar ou retardar a progressão do câncer em um indivíduo, composições farmacêuticas, kit, usos de uma combinação de um anticorpo anti-cd20 e de um anticorpo e invenção
EP3252078A1 (en) 2016-06-02 2017-12-06 F. Hoffmann-La Roche AG Type ii anti-cd20 antibody and anti-cd20/cd3 bispecific antibody for treatment of cancer
WO2018007314A1 (en) 2016-07-04 2018-01-11 F. Hoffmann-La Roche Ag Novel antibody format
JP7274413B2 (ja) * 2016-09-23 2023-05-16 マレンゴ・セラピューティクス，インコーポレーテッド ラムダ及びカッパ軽鎖を含む多重特異性抗体分子
WO2018060035A1 (en) 2016-09-30 2018-04-05 F. Hoffmann-La Roche Ag Spr-based dual-binding assay for the functional analysis of multispecific molecules
EP3519437B1 (en) 2016-09-30 2021-09-08 F. Hoffmann-La Roche AG Bispecific antibodies against p95her2
CN118359705A (zh) 2016-10-19 2024-07-19 英温拉公司 抗体构建体
CN110461868A (zh) 2016-11-01 2019-11-15 根马布私人有限公司 多肽变体及其用途
TW201829463A (zh) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 抗hla-g抗體及其用途
SG11201906961UA (en) 2017-02-10 2019-08-27 Genmab Bv Polypeptide variants and uses thereof
US20200291089A1 (en) 2017-02-16 2020-09-17 Elstar Therapeutics, Inc. Multifunctional molecules comprising a trimeric ligand and uses thereof
CN110382529B (zh) 2017-03-02 2024-03-08 诺华股份有限公司 工程化的异源二聚体蛋白质
MA48723A (fr) 2017-03-10 2020-04-08 Hoffmann La Roche Procédé de production d'anticorps multispécifiques
WO2018178396A1 (en) 2017-03-31 2018-10-04 Genmab Holding B.V. Bispecific anti-cd37 antibodies, monoclonal anti-cd37 antibodies and methods of use thereof
JP2020511988A (ja) * 2017-03-31 2020-04-23 ザ ボード オブ トラスティーズ オブ ザ レランド スタンフォード ジュニア ユニバーシティー シンセカイン組成物及び使用方法
WO2018184966A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Antibodies binding to steap-1
RS63663B1 (sr) 2017-04-03 2022-11-30 Hoffmann La Roche Imunokonjugati anti-pd-1 antitela sa mutantom il-2 ili sa il-15
WO2018184965A1 (en) 2017-04-03 2018-10-11 F. Hoffmann-La Roche Ag Immunoconjugates of il-2 with an anti-pd-1 and tim-3 bispecific antibody
CA3052532A1 (en) 2017-04-05 2018-10-11 F. Hoffmann-La Roche Ag Bispecific antibodies specifically binding to pd1 and lag3
CN110505883A (zh) 2017-04-13 2019-11-26 豪夫迈·罗氏有限公司 供治疗癌症的方法中使用的白介素-2免疫缀合物,cd40激动剂,和任选地pd-1轴结合拮抗剂
AR111963A1 (es) 2017-05-26 2019-09-04 Univ California Método y moléculas
US20210246227A1 (en) 2017-05-31 2021-08-12 Elstar Therapeutics, Inc. Multispecific molecules that bind to myeloproliferative leukemia (mpl) protein and uses thereof
WO2018224609A1 (en) 2017-06-07 2018-12-13 Genmab B.V. Therapeutic antibodies based on mutated igg hexamers
UY37758A (es) * 2017-06-12 2019-01-31 Novartis Ag Método de fabricación de anticuerpos biespecíficos, anticuerpos biespecíficos y uso terapéutico de dichos anticuerpos
WO2019000105A1 (en) 2017-06-30 2019-01-03 Zymeworks Inc. STABILIZED CHIMERIC FABES
AR112603A1 (es) 2017-07-10 2019-11-20 Lilly Co Eli Anticuerpos biespecíficos inhibidores de punto de control
WO2019014912A1 (zh) * 2017-07-21 2019-01-24 赵磊 一种异二聚体蛋白及其制备方法
WO2019028125A1 (en) * 2017-08-01 2019-02-07 Ab Studio Inc. BISPECIFIC ANTIBODIES AND USES THEREOF
WO2019035938A1 (en) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF
UA128389C2 (uk) * 2017-09-29 2024-07-03 Чугаі Сейяку Кабусікі Кайся Мультиспецифічна антигензв'язувальна молекула, яка має активність заміщувати кофакторну функцію фактора коагуляції крові viii (fviii), та фармацевтичний склад, який містить згадану молекулу як активний інгредієнт
EP3697441B1 (en) 2017-10-20 2023-06-07 F. Hoffmann-La Roche AG Method for generating multispecific antibodies from monospecific antibodies
BR112020007736A2 (pt) 2017-10-30 2020-10-20 F. Hoffmann-La Roche Ag composição e método de tratamento
EP3704150A1 (en) 2017-11-01 2020-09-09 F. Hoffmann-La Roche AG The compbody - a multivalent target binder
JP7092881B2 (ja) 2017-11-01 2022-06-28 エフ．ホフマン－ラ ロシュ アーゲー ＴｒｉＦａｂコントースボディ
US20210324108A1 (en) 2017-11-01 2021-10-21 Hoffmann-La Roche Inc. Bispecific 2+1 contorsbodies
JP2021500902A (ja) 2017-11-01 2021-01-14 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 新規ｔｎｆファミリーリガンド三量体含有抗原結合分子
SG11202005632SA (en) 2017-12-21 2020-07-29 Hoffmann La Roche Antibodies binding to hla-a2/wt1
WO2019122054A1 (en) 2017-12-22 2019-06-27 F. Hoffmann-La Roche Ag Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
JP2021510740A (ja) 2018-01-24 2021-04-30 ゲンマブ ビー．ブイ． ポリペプチド変種およびそれらの用途
WO2019154776A1 (en) 2018-02-06 2019-08-15 F. Hoffmann-La Roche Ag Treatment of ophthalmologic diseases
MX2020008289A (es) 2018-02-08 2020-09-25 Genentech Inc Moleculas biespecificas de union al antigeno y metodos de uso.
TWI829667B (zh) 2018-02-09 2024-01-21 瑞士商赫孚孟拉羅股份公司 結合gprc5d之抗體
EP3765516A2 (en) 2018-03-14 2021-01-20 Elstar Therapeutics, Inc. Multifunctional molecules and uses thereof
WO2019178362A1 (en) 2018-03-14 2019-09-19 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
CN112236448A (zh) 2018-04-17 2021-01-15 海德堡生物技术有限公司 用包含NC-1-Fc的蛋白寡聚体治疗血管发生、纤维化和癌症相关疾病的手段和方法
WO2019204522A1 (en) * 2018-04-17 2019-10-24 Invenra Inc. Binding molecules
AR115052A1 (es) 2018-04-18 2020-11-25 Hoffmann La Roche Anticuerpos multiespecíficos y utilización de los mismos
KR20210008380A (ko) 2018-05-03 2021-01-21 젠맵 비. 브이 항체 변이체 조합물 및 그의 용도
KR20210011002A (ko) 2018-05-16 2021-01-29 얀센 바이오테크 인코포레이티드 암을 치료하는 방법 및 t-세포 재유도 치료제의 효능을 향상시키는 방법
TWI848953B (zh) 2018-06-09 2024-07-21 德商百靈佳殷格翰國際股份有限公司 針對癌症治療之多特異性結合蛋白
WO2019243636A1 (en) 2018-06-22 2019-12-26 Genmab Holding B.V. Anti-cd37 antibodies and anti-cd20 antibodies, compositions and methods of use thereof
DE202019005887U1 (de) 2018-07-03 2023-06-14 Marengo Therapeutics, Inc. Anti-TCR-Antikörpermoleküle und Verwendungen davon
CA3106146A1 (en) 2018-07-13 2020-01-16 Genmab A/S Variants of cd38 antibody and uses thereof
JP7534281B2 (ja) 2018-07-13 2024-08-14 ジェンマブ エー／エス Ｃｄ３８抗体を使用したトロゴサイトーシスを介した治療
JP7522106B2 (ja) 2018-10-04 2024-07-24 ジェンマブ ホールディング ビー．ブイ． 二重特異性抗ｃｄ３７抗体を含む医薬組成物
WO2020084032A1 (en) * 2018-10-25 2020-04-30 F. Hoffmann-La Roche Ag Modification of antibody fcrn binding
WO2020089051A1 (en) 2018-10-29 2020-05-07 F. Hoffmann-La Roche Ag Antibody formulation
MX2021005085A (es) 2018-11-06 2021-11-04 Genmab As Formulacion de anticuerpo.
EP3891186A1 (en) 2018-12-05 2021-10-13 MorphoSys AG Multispecific antigen-binding molecules
EP3897847A1 (en) 2018-12-21 2021-10-27 F. Hoffmann-La Roche AG Antibodies binding to cd3
EP3674319A1 (en) 2018-12-24 2020-07-01 Sanofi Pseudofab-based multispecific binding proteins
CA3124770A1 (en) 2018-12-24 2020-07-02 Sanofi Pseudofab-based multispecific binding proteins
AU2019412561A1 (en) 2018-12-24 2021-08-12 Sanofi Multispecific binding proteins with mutant Fab domains
EP3674316A1 (en) 2018-12-24 2020-07-01 Sanofi Multispecific binding proteins with mutant fab domains
AU2019413278A1 (en) 2018-12-28 2021-07-15 Kyowa Kirin Co., Ltd. Bispecific antibody binding to TfR
WO2020136060A1 (en) 2018-12-28 2020-07-02 F. Hoffmann-La Roche Ag A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
CN113573729A (zh) 2019-01-10 2021-10-29 詹森生物科技公司 前列腺新抗原及其用途
GB2599227B (en) 2019-02-21 2024-05-01 Marengo Therapeutics Inc Multifunctional molecules that bind to T cells and uses thereof to treat autoimmune disorders
CN114126714A (zh) 2019-02-21 2022-03-01 马伦戈治疗公司 抗tcr抗体分子及其用途
SG11202108955QA (en) 2019-02-21 2021-09-29 Marengo Therapeutics Inc Antibody molecules that bind to nkp30 and uses thereof
WO2020172571A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to t cell related cancer cells and uses thereof
WO2020172601A1 (en) 2019-02-21 2020-08-27 Elstar Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
JP7249432B2 (ja) 2019-03-29 2023-03-30 エフ． ホフマン－ラ ロシュ アーゲー 多価分子の機能分析のための、ｓｐｒをベースとする結合アッセイ
CN113677701A (zh) 2019-03-29 2021-11-19 豪夫迈·罗氏有限公司 产生亲合结合多特异性抗体的方法
AU2020262309A1 (en) 2019-04-25 2021-10-14 F. Hoffmann-La Roche Ag Therapeutic multispecific polypeptides activated by polypeptide chain exchange
TW202106713A (zh) 2019-04-25 2021-02-16 瑞士商赫孚孟拉羅股份公司 具延長半衰期之可活化治療性多特異性多肽
KR20220005031A (ko) 2019-04-25 2022-01-12 에프. 호프만-라 로슈 아게 폴리펩티드 사슬 교환에 의한 항체-유래된 폴리펩티드의 산출
US20220315661A1 (en) 2019-05-09 2022-10-06 Genmab B.V. Dosage regimens for a combination of anti-dr5 antibodies for use in treating cancer
EP3969907A1 (en) 2019-05-13 2022-03-23 F. Hoffmann-La Roche AG Interference-suppressed pharmacokinetic immunoassay
CN114080451B (zh) 2019-06-19 2024-03-22 豪夫迈·罗氏有限公司 通过使用Cre mRNA进行的靶向整合来产生蛋白质表达细胞的方法
MX2021015823A (es) 2019-06-26 2022-02-03 Hoffmann La Roche Lineas celulares de mamifero con inactivacion del gen sirtuina-1 (sirt-1).
EP3994169A1 (en) 2019-07-02 2022-05-11 F. Hoffmann-La Roche AG Immunoconjugates comprising a mutant interleukin-2 and an anti-cd8 antibody
AR119393A1 (es) 2019-07-15 2021-12-15 Hoffmann La Roche Anticuerpos que se unen a nkg2d
MX2022001049A (es) 2019-07-26 2022-05-03 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de la peptidasa 2 relacionada con la calicreína y sus usos.
CN114174338A (zh) 2019-07-31 2022-03-11 豪夫迈·罗氏有限公司 与gprc5d结合的抗体
PE20220394A1 (es) 2019-07-31 2022-03-18 Hoffmann La Roche Anticuerpos que se fijan a gprc5d
KR20220062494A (ko) 2019-08-15 2022-05-17 얀센 바이오테크 인코포레이티드 개선된 단일 사슬 가변 단편을 위한 재료 및 방법
US20210077697A1 (en) * 2019-09-12 2021-03-18 Fresenius Medical Care Deutschland Gmbh System and method for connecting a concentrate container with a blood treatment device without leakages
US20220411529A1 (en) 2019-11-06 2022-12-29 Genmab B.V. Antibody variant combinations and uses thereof
KR20220113791A (ko) 2019-12-18 2022-08-16 에프. 호프만-라 로슈 아게 이중특이적 항-ccl2 항체
AU2020406085A1 (en) 2019-12-18 2022-05-26 F. Hoffmann-La Roche Ag Antibodies binding to HLA-A2/MAGE-A4
CN115003693A (zh) * 2019-12-20 2022-09-02 加拿大商木曾路生物科技公司 多肽、蛋白质复合物及其制造方法
EP4085251B1 (en) 2020-01-02 2024-07-31 F. Hoffmann-La Roche AG Method for determining the amount of a therapeutic antibody in the brain
WO2021138407A2 (en) 2020-01-03 2021-07-08 Marengo Therapeutics, Inc. Multifunctional molecules that bind to cd33 and uses thereof
CA3165660A1 (en) 2020-01-16 2021-07-22 Genmab A/S Formulations of cd38 antibodies and uses thereof
IL295129A (en) 2020-01-30 2022-09-01 Umoja Biopharma Inc Bispecific transduction enhancer
TW202144388A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在卵巢癌中表現之新抗原及其用途
TW202144389A (zh) 2020-02-14 2021-12-01 美商健生生物科技公司 在多發性骨髓瘤中表現之新抗原及其用途
KR20220154728A (ko) 2020-03-13 2022-11-22 얀센 바이오테크 인코포레이티드 Siglec-3/cd33을 결합시키기 위한 물질 및 방법
WO2021209402A2 (en) 2020-04-15 2021-10-21 F. Hoffmann-La Roche Ag Immunoconjugates
EP4139363A4 (en) 2020-04-24 2024-09-04 Marengo Therapeutics Inc MULTIFUNCTIONAL MOLECULES BINDING TO T-CELL ASSOCIATED CANCER CELLS AND USES THEREOF
WO2021222552A1 (en) 2020-04-30 2021-11-04 Celgene Corporation Methods of treating cytokine-related adverse events
AU2021272340A1 (en) 2020-05-11 2022-12-08 F. Hoffmann-La Roche Ag Combination therapy with modified pbmcs and an immunoconjugate
TW202210510A (zh) 2020-05-27 2022-03-16 美商健生生物科技公司 包含ｃｄ３抗原結合域之蛋白質及其用途
CR20220637A (es) 2020-06-19 2023-01-31 Hoffmann La Roche Anticuerpos que se unen a cd3 y cd19
CN115916827A (zh) 2020-06-19 2023-04-04 豪夫迈·罗氏有限公司 免疫活化Fc结构域结合分子
KR20230025673A (ko) 2020-06-19 2023-02-22 에프. 호프만-라 로슈 아게 CD3 및 FolR1에 결합하는 항체
WO2021255146A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3 and cea
CA3176579A1 (en) 2020-06-19 2021-12-23 F. Hoffmann-La Roche Ag Antibodies binding to cd3
JP2023534726A (ja) 2020-07-23 2023-08-10 ジェンマブ ビー．ブイ． 多発性骨髄腫の治療に使用するための抗ｄｒ５抗体と免疫調節イミド薬との併用
TW202221028A (zh) 2020-07-29 2022-06-01 美商健生生物科技公司 包括hla-g抗原結合域之蛋白及其用途
WO2022046920A2 (en) 2020-08-26 2022-03-03 Marengo Therapeutics, Inc. Multifunctional molecules that bind to calreticulin and uses thereof
EP4204096A4 (en) 2020-08-26 2024-10-02 Marengo Therapeutics Inc ANTIBODY MOLECULES BINDING TO NKP30 AND RELATED USES
CA3190573A1 (en) 2020-08-26 2022-03-03 Andreas Loew Methods of detecting trbc1 or trbc2
KR20230068415A (ko) 2020-09-24 2023-05-17 에프. 호프만-라 로슈 아게 유전자 녹아웃을 갖는 포유류 세포주
JP2023547329A (ja) 2020-10-02 2023-11-10 ジェンマブ エー／エス Ｒｏｒ２へと結合することができる抗体ならびにｒｏｒ２およびｃｄ３に結合する二重特異性抗体
KR20230104617A (ko) * 2020-10-07 2023-07-10 드렌 바이오, 인크. 항-덱틴-1 항체 및 이의 사용 방법
CN116635052A (zh) 2020-10-13 2023-08-22 詹森生物科技公司 用于调节分化簇iv和/或viii的生物工程t细胞介导的免疫、材料和其他方法
WO2022084915A1 (en) 2020-10-22 2022-04-28 Janssen Biotech, Inc. Proteins comprising delta-like ligand 3 (dll3) antigen binding domains and their uses
CA3200603A1 (en) * 2020-11-10 2022-05-19 Amgen Inc. Novel linkers of multispecific antigen binding domains
WO2022100613A1 (zh) 2020-11-10 2022-05-19 上海齐鲁制药研究中心有限公司 针对密蛋白18a2和cd3的双特异性抗体及其应用
WO2022104367A1 (en) * 2020-11-12 2022-05-19 Northwestern University Cell-free expression of antibodies, antigen-binding fragments thereof, and antibody derivatives
CN114539413A (zh) * 2020-11-25 2022-05-27 三生国健药业（上海）股份有限公司 结合her2的多价双特异性抗体、其制备方法和用途
JP7326584B2 (ja) 2020-12-17 2023-08-15 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｈｌａ－ｇ抗体及びその使用
EP4263595A1 (en) 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Precursor proteins and kit for targeted therapy
WO2022136140A1 (en) 2020-12-22 2022-06-30 F. Hoffmann-La Roche Ag Oligonucleotides targeting xbp1
EP4274658A1 (en) 2021-01-06 2023-11-15 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and a cd20 t cell bispecific antibody
WO2022148853A1 (en) 2021-01-11 2022-07-14 F. Hoffmann-La Roche Ag Immunoconjugates
MX2023009211A (es) * 2021-02-05 2023-08-22 Phanes Therapeutics Inc Anticuerpos biespecificos con pares de carga y usos de los mismos.
JP2024512240A (ja) 2021-02-18 2024-03-19 エフ． ホフマン－ラ ロシュ アーゲー 複雑な多段階の抗体相互作用を解明するための方法
WO2022201053A1 (en) 2021-03-24 2022-09-29 Janssen Biotech, Inc. Proteins comprising cd3 antigen binding domains and uses thereof
US20240301031A1 (en) 2021-03-31 2024-09-12 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Truncated taci polypeptide and fusion protein and use thereof
AU2022255506A1 (en) 2021-04-08 2023-11-09 Marengo Therapeutics, Inc. Multifunctional molecules binding to tcr and uses thereof
CN117651714A (zh) * 2021-04-20 2024-03-05 美国安进公司 多特异性和单价IgG分子组装中链配对的静电转向中的平衡电荷分布
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
MX2023012699A (es) 2021-04-30 2023-11-21 Hoffmann La Roche Dosificacion para el tratamiento con anticuerpo biespecifico anti-cd20/anti-cd3.
TW202306990A (zh) 2021-05-12 2023-02-16 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｒａｎｋｌ和ｎｇｆ的抗原結合分子及其醫藥用途
MX2023013307A (es) 2021-05-14 2023-12-04 Jiangsu Hengrui Pharmaceuticals Co Ltd Molecula de union a antigeno.
KR20240021859A (ko) 2021-06-18 2024-02-19 에프. 호프만-라 로슈 아게 이중특이적 항-ccl2 항체
TW202309078A (zh) 2021-07-02 2023-03-01 美商建南德克公司 治療癌症之方法及組成物
WO2023284829A1 (zh) 2021-07-14 2023-01-19 江苏恒瑞医药股份有限公司 特异性结合hgfr和egfr的抗原结合分子及其医药用途
AU2022315528A1 (en) 2021-07-22 2023-10-19 F. Hoffmann-La Roche Ag Heterodimeric fc domain antibodies
JP2024527977A (ja) 2021-07-27 2024-07-26 ノヴァブ， インコーポレイテッド 免疫エフェクター機能を有する操作されたｖｌｒｂ抗体
WO2023006809A1 (en) 2021-07-27 2023-02-02 Morphosys Ag Combinations of antigen binding molecules
MX2024001214A (es) 2021-07-28 2024-02-12 Hoffmann La Roche Metodos y composiciones para tratar cancer.
JP2024533234A (ja) 2021-09-06 2024-09-12 ジェンマブ エー／エス Ｃｄ２７に結合する能力を有する抗体、そのバリアントおよびその使用
JP2024533457A (ja) 2021-09-13 2024-09-12 ヤンセン バイオテツク，インコーポレーテツド がんの治療のためのＣＤ３３×Ｖδ２多重特異性抗体
CN117813323A (zh) 2021-09-23 2024-04-02 江苏恒瑞医药股份有限公司 抗klb抗体及用途
EP4405392A1 (en) 2021-09-24 2024-07-31 Janssen Biotech, Inc. Proteins comprising cd20 binding domains, and uses thereof
EP4410841A1 (en) 2021-09-30 2024-08-07 Jiangsu Hengrui Pharmaceuticals Co., Ltd. Anti-il23 antibody fusion protein and uses thereof
EP4429706A1 (en) 2021-10-14 2024-09-18 F. Hoffmann-La Roche AG Alternative pd1-il7v immunoconjugates for the treatment of cancer
KR20240082349A (ko) 2021-10-14 2024-06-10 에프. 호프만-라 로슈 아게 새로운 인터루킨-7 면역접합체
AU2022380722A1 (en) 2021-11-03 2024-06-20 Janssen Biotech, Inc. Methods of treating cancers and enhancing efficacy of bcmaxcd3 bispecific antibodies
IL312566A (en) 2021-11-10 2024-07-01 Astrazeneca Ab molecules and antibodies
EP4436669A1 (en) 2021-11-22 2024-10-02 Janssen Biotech, Inc. Compositions comprising enhanced multispecific binding agents for an immune response
WO2023094282A1 (en) 2021-11-25 2023-06-01 F. Hoffmann-La Roche Ag Quantification of low amounts of antibody sideproducts
AR127887A1 (es) 2021-12-10 2024-03-06 Hoffmann La Roche Anticuerpos que se unen a cd3 y plap
TW202337902A (zh) 2022-02-07 2023-10-01 大陸商江蘇恆瑞醫藥股份有限公司 特異性結合ｐｓｍａ和ｃｄ３的抗原結合分子及其醫藥用途
WO2023151661A1 (zh) 2022-02-11 2023-08-17 江苏恒瑞医药股份有限公司 免疫缀合物及其用途
WO2023175064A1 (en) 2022-03-17 2023-09-21 Astrazeneca Ab Methods for purifying bispecific antibodies
US20230414750A1 (en) 2022-03-23 2023-12-28 Hoffmann-La Roche Inc. Combination treatment of an anti-cd20/anti-cd3 bispecific antibody and chemotherapy
AU2023251832A1 (en) 2022-04-13 2024-10-17 F. Hoffmann-La Roche Ag Pharmaceutical compositions of anti-cd20/anti-cd3 bispecific antibodies and methods of use
WO2023202967A1 (en) 2022-04-19 2023-10-26 F. Hoffmann-La Roche Ag Improved production cells
TW202413412A (zh) 2022-05-12 2024-04-01 丹麥商珍美寶股份有限公司 在組合療法中能夠結合到ｃｄ２７之結合劑
WO2023218051A1 (en) 2022-05-12 2023-11-16 Genmab A/S Binding agents capable of binding to cd27 in combination therapy
WO2023232961A1 (en) 2022-06-03 2023-12-07 F. Hoffmann-La Roche Ag Improved production cells
TW202417040A (zh) 2022-06-27 2024-05-01 瑞典商阿斯特捷利康公司 涉及用於治療癌症的上皮生長因子受體酪胺酸激酶抑制劑之組合
WO2024017371A1 (zh) * 2022-07-22 2024-01-25 信达生物制药(苏州)有限公司 促进多特异性抗体的重链和轻链同源配对的突变体
WO2024023750A1 (en) 2022-07-28 2024-02-01 Astrazeneca Uk Limited Combination of antibody-drug conjugate and bispecific checkpoint inhibitor
CN117820490A (zh) * 2022-09-28 2024-04-05 科兴生物制药股份有限公司 Vegf和ang-2双特异性抗体及其应用
WO2024079015A1 (en) 2022-10-10 2024-04-18 F. Hoffmann-La Roche Ag Combination therapy of a gprc5d tcb and imids
TW202423969A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及蛋白酶體抑制劑之組合療法
TW202423970A (zh) 2022-10-10 2024-06-16 瑞士商赫孚孟拉羅股份公司 Ｇｐｒｃ５ｄ ｔｃｂ及ｃｄ３８抗體之組合療法
WO2024079069A1 (en) 2022-10-12 2024-04-18 F. Hoffmann-La Roche Ag Method for classifying cells
WO2024094660A1 (en) 2022-10-31 2024-05-10 Genmab A/S Cd38 antibodies and uses thereof
WO2024095173A1 (en) 2022-11-02 2024-05-10 Janssen Biotech, Inc. Methods of treating cancers
WO2024100170A1 (en) 2022-11-11 2024-05-16 F. Hoffmann-La Roche Ag Antibodies binding to hla-a*02/foxp3
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules
WO2024104988A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Recombinant binding proteins with activatable effector domain
WO2024104933A1 (en) 2022-11-15 2024-05-23 F. Hoffmann-La Roche Ag Antigen binding molecules
WO2024153722A1 (en) 2023-01-20 2024-07-25 F. Hoffmann-La Roche Ag Immunoconjugates
WO2024156672A1 (en) 2023-01-25 2024-08-02 F. Hoffmann-La Roche Ag Antibodies binding to csf1r and cd3
WO2024163494A1 (en) 2023-01-31 2024-08-08 F. Hoffmann-La Roche Ag Methods and compositions for treating non-small cell lung cancer and triple-negative breast cancer
WO2024163009A1 (en) 2023-01-31 2024-08-08 Genentech, Inc. Methods and compositions for treating urothelial bladder cancer
WO2024184287A1 (en) 2023-03-06 2024-09-12 F. Hoffmann-La Roche Ag Combination therapy of an anti-egfrviii/anti-cd3 antibody and an tumor-targeted 4-1bb agonist
WO2024188965A1 (en) 2023-03-13 2024-09-19 F. Hoffmann-La Roche Ag Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody
WO2024208777A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag All-in-one agonistic antibodies
WO2024208776A1 (en) 2023-04-03 2024-10-10 F. Hoffmann-La Roche Ag Agonistic split antibodies

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3101690B2 (ja) 1987-03-18 2000-10-23 エス・ビィ・２・インコーポレイテッド 変性抗体の、または変性抗体に関する改良
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
EP0640094A1 (en) 1992-04-24 1995-03-01 The Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
DE4425115A1 (de) * 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
US20020062010A1 (en) 1997-05-02 2002-05-23 Genentech, Inc. Method for making multispecific antibodies having heteromultimeric and common components
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU3657899A (en) 1998-04-20 1999-11-08 James E. Bailey Glycosylation engineering of antibodies for improving antibody-dependent cellular cytotoxicity
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
KR101155191B1 (ko) 1999-01-15 2012-06-13 제넨테크, 인크. 효과기 기능이 변화된 폴리펩티드 변이체
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
ES2571230T3 (es) 1999-04-09 2016-05-24 Kyowa Hakko Kirin Co Ltd Procedimiento para controlar la actividad de una molécula inmunofuncional
WO2001029246A1 (fr) 1999-10-19 2001-04-26 Kyowa Hakko Kogyo Co., Ltd. Procede de production d'un polypeptide
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
DE60143544D1 (de) 2000-12-12 2011-01-05 Medimmune Llc Moleküle mit längeren halbwertszeiten, zusammensetzungen und deren verwendung
US20030003097A1 (en) 2001-04-02 2003-01-02 Idec Pharmaceutical Corporation Recombinant antibodies coexpressed with GnTIII
HUP0600342A3 (en) 2001-10-25 2011-03-28 Genentech Inc Glycoprotein compositions
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
CA2849556A1 (en) 2002-04-11 2003-10-23 Vu Truong-Le Preservation of bioactive materials by freeze dried foam
KR20050011741A (ko) 2002-04-11 2005-01-29 메드이뮨 백신즈 인코포레이티드 분무 건조에 의한 생물학적 활성 물질의 보존
EP1581639A4 (en) 2002-12-17 2006-03-08 Medimmune Vaccines Inc HIGH PRESSURE PULVISATION OF BIOACTIVE MATERIALS
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
US20050226867A1 (en) 2003-10-08 2005-10-13 Kyowa Hakko Kogyo Co., Ltd. IL-5R-specific antibody composition
LT2348051T (lt) 2003-11-05 2019-02-25 Roche Glycart Ag Cd20 antikūnai su padidintu fc receptoriaus prisijungimo giminingumu ir efektorine funkcija
DK1896071T3 (en) 2005-06-30 2015-05-26 Janssen Biotech Inc Methods and compositions with increased therapeutic activity
GB0514779D0 (en) * 2005-07-19 2005-08-24 Celltech R&D Ltd Biological products
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
JP5474531B2 (ja) 2006-03-24 2014-04-16 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 操作されたヘテロ二量体タンパク質ドメイン
US20090182127A1 (en) 2006-06-22 2009-07-16 Novo Nordisk A/S Production of Bispecific Antibodies
MX2010002683A (es) 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
WO2010115589A1 (en) 2009-04-07 2010-10-14 Roche Glycart Ag Trivalent, bispecific antibodies
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
CN107337734A (zh) * 2009-12-04 2017-11-10 弗·哈夫曼-拉罗切有限公司 多特异性抗体、抗体类似物、组合物和方法
PL2519543T3 (pl) * 2009-12-29 2016-12-30 Białka wiążące heterodimery i ich zastosowania
TR201903279T4 (tr) 2010-03-25 2019-03-21 Ucb Biopharma Sprl Disülfür stabilize edilmiş DVD-IG molekülleri.
JP5767207B2 (ja) * 2010-03-26 2015-08-19 協和発酵キリン株式会社 新規修飾部位導入抗体および抗体フラグメント
ES2617777T5 (es) * 2010-04-23 2022-10-13 Hoffmann La Roche Producción de proteínas heteromultiméricas
MX338953B (es) 2010-08-16 2016-05-06 Novimmune Sa Metodos para la generacion de anticuerpos multiespecificos y multivalentes.

Also Published As

Publication number Publication date
SI2794905T1 (sl) 2020-08-31
EP2794905A4 (en) 2015-11-18
WO2013096291A2 (en) 2013-06-27
WO2013096291A3 (en) 2013-09-19
EP2794905B1 (en) 2020-04-01
CN104011221B (zh) 2019-01-08
RS60499B1 (sr) 2020-08-31
PT2794905T (pt) 2020-06-30
HUE049457T2 (hu) 2020-09-28
ES2816078T3 (es) 2021-03-31
HRP20201004T1 (hr) 2020-10-16
LT2794905T (lt) 2020-07-10
US20140348839A1 (en) 2014-11-27
CA2859667A1 (en) 2013-06-27
DK2794905T3 (da) 2020-07-06
AU2012355415B2 (en) 2017-07-06
CA2859667C (en) 2022-05-24
CN104011221A (zh) 2014-08-27
AU2012355415A1 (en) 2014-07-17
JP2015502409A (ja) 2015-01-22
EP2794905A2 (en) 2014-10-29
CY1123079T1 (el) 2021-10-29
PL2794905T3 (pl) 2020-11-02
US9527927B2 (en) 2016-12-27
JP6541974B2 (ja) 2019-07-10

Similar Documents

Publication Publication Date Title
HK1203560A1 (zh) 用於雙特異性抗體支架的經修飾的多肽
HK1253911A1 (zh) 抗α4β7抗體的製劑
HRP20180640T1 (hr) Anti-b7-h3 antitijelo
HK1249466A1 (zh) 抗α4β7抗體的製劑
IL259826A (en) Anti-alphabetatisiar antibody
SI2794658T1 (sl) Bispecifična molekula protitelesa
EP2922874A4 (en) BISPECIFIC ANTIBODIES
GB201103955D0 (en) Antibodies
GB201112056D0 (en) Antibodies
ZA201407272B (en) Anti-baff-anti-il-17 bispecific antibodies
TWI563004B (en) Anti-hxcr1 antibody
EP2707392A4 (en) MONOCLONAL ANTIBODY FOR ACETYLAMANTADINE
EP2757373A4 (en) METHOD FOR MEASURING ANTI-WT1 ANTIBODIES
EP2769988A4 (en) ANTI-GAP43 ANTIBODY
EP2714074A4 (en) ANTIBODIES AGAINST EMR1